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Abstract
Background: All mucosal epithelia, including those of the tubotympanium, are secreting a variety
of antimicrobial innate immune molecules (AIIMs). In our previous study, we showed the
bactericidal/bacteriostatic functions of AIIMs against various otitis media pathogens. Among the
AIIMs, human β-defensin 2 is the most potent molecule and is inducible by exposure to
inflammatory stimuli such as bacterial components or proinflammatory cytokines. Even though the
β-defensin 2 is an important AIIM, the induction mechanism of this molecule has not been clearly
established. We believe that this report is the first attempt to elucidate NTHi induced β-defensin
expression in airway mucosa, which includes the middle ear.
Methods: Monoclonal antibody blocking method was employed in monitoring the TLR-dependent
NTHi response. Two gene knock down methods – dominant negative (DN) plasmid and small
interfering RNA (siRNA) – were employed to detect and confirm the involvement of several key
genes in the signaling cascade resulting from the NTHi stimulated β-defensin 2 expression in human
middle ear epithelial cell (HMEEC-1). The student's t-test was used for the statistical analysis of the
data.
Results: The experimental results showed that the major NTHi-specific receptor in HMEEC-1 is
the Toll-like receptor 2 (TLR2). Furthermore, recognition of NTHi component(s)/ligand(s) by
TLR2, activated the Toll/IL-1 receptor (TIR)-MyD88-IRAK1-TRAF6-MKK3/6-p38 MAPK signal
transduction pathway, ultimately leading to the induction of β-defensin 2.
Conclusion: This study found that the induction of β-defensin 2 is highest in whole cell lysate
(WCL) preparations of NTHi, suggesting that the ligand(s) responsible for this up-regulation may
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be soluble macromolecule(s). We also found that this induction takes place through the TLR2
dependent MyD88-IRAK1-TRAF6-p38 MAPK pathway, with the primary response occurring within
the first hour of stimulation. In combination with our previous studies showing that IL-1α-induced
β-defensin 2 expression takes place through a MyD88-independent Raf-MEK1/2-ERK MAPK
pathway, we found that both signaling cascades act synergistically to up-regulate β-defensin 2 levels.
We propose that this confers an essential evolutionary advantage to the cells in coping with
infections and may serve to amplify the innate immune response through paracrine signaling.
Background
The respiratory mucosal epithelia, including the middle
ear mucosa, are directly exposed to the environment and
serve as an effective first line of defense against a variety of
potentially pathogenic microorganisms. Second only to
the common cold, otitis media (OM) is the most preva-
lent mucosal infectious disease affecting young children.
OM results in 31 million annual visits to physicians'
offices and is estimated to have a yearly cost exceeding $5
billion USD. Nontypeable Haemophilus influenzae (NTHi)
[1,2] is one of the major OM pathogens and is also a caus-
ing agent for sinusitis and chronic obstructive pulmonary
disease (COPD) [3]. In the past three decades, there has
been a dramatic worldwide increase in antibiotic resist-
ance in respiratory pathogens. There is, thus, an urgent
need to develop new and innovative, non-antibiotic
approaches to prevent and manage this disease [4,5]. The
pathogenesis of OM is multi-factorial and it is believed
that the antimicrobial innate immune molecules (AIIMs)
[6-11] as well as pathogen recognition receptors such as
the toll-like receptors (TLR) are playing roles in OM sus-
ceptibility [3,12,13].
Innate immune molecules such as lysozyme, lactoferrin,
PLUNC (palate, lung and nasal epithelium clone) and
defensins are produced by the mucosal epithelial cells and
provide the host with continuous innate immunity
against a variety of invading pathogens [14,15]. Among
the AIIMs, the β-defensin family is one of the most potent
innate immune molecules [16-18]. Some of the major
roles defensins play in host defense are direct antimicro-
bial activity, facilitation and amplification of innate and
adaptive immunity [19-22]. To date, multiple β-defensin
genes from epithelial and epididymal cells have been
identified [23-25]. Among them, four of epithelial β-
defensins (HBD 1–4) have been characterized at the pep-
tide level [23,24,26]. β-defensin 1 is expressed constitu-
tively by a variety of cell types, while β-defensin 2
expression is highly up-regulated by exposure to inflam-
matory stimuli such as bacterial components or proin-
flammatory cytokines [20,23]. We have recently shown
that both human β-defensin 1 and 2 (HBD-1 and -2) have
bactericidal/bacteriostatic activity against NTHi [14].
Moreover, in a previous study, we demonstrated that IL-
1α up-regulates the transcription of HBD-2 in human
middle ear epithelial cells (HMEEC-1), through the Src
dependent Raf-MEK1/2-ERK signaling pathway [27].
However, despite this common generality, the degree of
HBD-2 induction was variable in different cell types in
response to inflammatory signal [20,28]. In human skin
keratinocytes, the E. coli LPS is a weak inducer of HBD-2
signaling, but the induction is greatly increased when
monocyte-derived cells were used as intermediaries
between LPS and the epidermal keratinocytes. This may
be due to the facts that the amplified epidermal response
to LPS is mediated through the IL-1 pathway which is the
dominant inducer of HBD-2 [20,29,30]. It is possible that
HBD-2 and IL-1 signal amplification is mediated through
TLRs.
The innate immune system has been known to utilize the
Toll-like receptors (TLRs) for recognition of pathogen-
associated molecular patterns (PAMPs), thus activating
the MAPK or the NF-kB-dependent cell signaling cascades,
resulting in a rapid, full-blown proinflammatory response
[19]. TLR proteins are a family of type I trans-membrane
receptors consisting of an NH2-terminal extracellular leu-
cine-rich repeat domain (LRR) and a COOH-terminal
intracellular Toll/IL-1 receptor (TIR) homology domain
[31,32]. The intracellular TIR domain is a region of 150
amino acids with three highly conserved regions [33].
This TIR domain plays an important role in mediating
protein-protein interactions between TLR proteins and
their downstream signal transduction components such
as the MyD88 protein [13]. The MyD88 recruited via its
TIR domain to the TLR receptor promotes association
with the interleukin-1 receptor-associated kinase 1
(IRAK1) [13,34]. The phosphorylation of IRAK1 results in
its dissociation from the complex and its interaction with
the tumor necrosis factor receptor-associated factor 6
(TRAF6) [13,34]. Activation of the TLR2-MyD88-IRAK1-
TRAF6 can lead to the activation of many downstream sig-
naling pathways, including members of the mitogen-acti-
vated protein kinase (MAPK) family [19,35]. At least three
MAPK families have been identified to date: extracellular
signal-regulated kinase (ERK), c-Jun kinase (JNK/SAPK)
and p38 MAPK [19]. Among the three possible MAPK
pathways, we hypothesize that NTHi WCL-induced HBD-
2 up-regulation in HMEEC-1 takes place through the p38
MAPK cascade. Furthermore, TIR-like motifs in receptorsBMC Infectious Diseases 2008, 8:87 http://www.biomedcentral.com/1471-2334/8/87
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from various plant species have also been shown to confer
disease resistance [33], indicating a evolutionarily con-
served functional role for this domain across species. Even
though the IL-1 receptor and TLR are composed of differ-
ent extracellular receptors, similarities between their intra-
cellular TIR domains leads them to exhibit similar
immunological responses [32]. This fact leads us to
hypothesize that the possible interaction of the two
domains is important to the synergistic induction of
HBD-2.
In this study we show that NTHi12 induced HBD-2 up-
regulation mainly takes place through the TLR2-MyD88-
IRAK1-TRAF6-MKK3/6-p38 MAPK pathway. This result
may also explain the significant synergistic effects of NTHi
and IL-1α co-stimulation in expression and regulation of
HBD-2 [30].
Methods
Bacterial culture and preparation of whole cell lysate
The NTHi strain 12 used in this study is a clinical isolate
and it has been well documented [14,36,37]. The prepara-
tion procedure was described in a previous paper [14].
Briefly, stocks of NTHi 12 (obtained from Dr. Steve
Barenkamp, St. Louis University, School of Medicine)
were maintained at -80°C. The bacteria were plated on
chocolate agar and incubated overnight at 37°C in 5%
CO2. A single colony was used to inoculate 10 ml of brain
heart infusion (BHI, Becton Dickinson, Cockeysville,
MD), supplemented with hemin (10 μg/ml, Sigma, St.
Louis, MO) and nicotinamide adenine dinucleotide
(NAD10 μg/ml, Sigma, St. Louis, MO), and allowed to
grow overnight. The bacteria were collected at 5,000 × g
for 10 min and washed three times in phosphate buffered
saline (PBS). After sonication, the lysate was cleared by
centrifugation at 10,000 × g for 10 min. The cleared whole
cell lysate (WCL) was collected and stored at -80°C and
the pellet (P) was resuspended in PBS. To compare varia-
tions of HBD-2 induction by different NTHi strains, we
prepared WCL from NTHi 2019 and NTHi 9274 (kind
gifts from Dr. Michael Apicella, The university of Iowa,
Department of Microbiology) using the same method
described above [38-40].
Mammalian epithelial cell culture
The human middle ear epithelial cell line (HMEEC-1)
used in this study was immortalized with the E6/E7 genes
of human papilloma virus type 16 and has been used in
number of cell signaling studies [27,30,41,42]. HMEEC-1
cells were maintained in a 1:1 mixture of Dulbecco's mod-
ified Eagle's medium (DMEM) (Life Technologies, Inc,
Gaithersburg, MD) and Bronchial Epithelial Basal
Medium (BEBM) (Clonetics, Walkersville, MD) supple-
mented with bovine pituitary extract (52 μg/ml), hydro-
cortisone (0.5 μg/ml), hEGF (0.5 ng/ml), epinephrine 0.5
(μg/ml), transferrin (10 μg/ml), insulin (5 μg/ml), triio-
dothyronine (6.5 ng/ml), retinoic acid (0.1 ng/ml), gen-
tamycin (50 μg/ml) and amphotericin-B (50 ng/ml). All
cells were cultured in a humidified atmosphere of 5%
CO2 and 95% air. A549 (human lung carcinoma) cell
lines were cultured in DMEM supplemented with 5% fetal
bovine serum (Life Technologies, Inc., Gaithersburg,
MD).
Blocking TLR2/TLR4 with monoclonal-Antibody
HMEEC-1 cells were cultured to 80% confluence and
treated with 10 μg/ml of human TLR2 or TLR4 blocking
antibodies (eBioscience, San Diego, CA) for 30 minutes at
room temperature followed by stimulation with 5 μg/ml
NTHi WCL for 4 hours. Isogenic antibody (IgG2a, k) was
used as the control. All experiments were done in tripli-
cates.
Plasmid transfection and chemical inhibitors
HMEEC-1 cells were cultured in 12 well plates for 24
hours and then transiently transfected with appropriate
dominant-negative mutant (DN) plasmids – hTLR2 DN,
MyD88 DN, and TRAF6 DN (described previously
[43,44]) and hTLR4 DN and IRAK1 DN (kindly provided
by Dr. Jian-Dong Li) and pcDNA3.1 (Invitrogen,
Carlsbad, CA) served as the control. All transient transfec-
tions were carried out in triplicate using a concentration of
1 μg/ml of plasmid and TransIT-LT1 reagent (Mirus, Mad-
ison, WI) following the manufacturer's instructions. 42
hours after transfection, 5 μg/ml of NTHi WCL was added
to the cells for 4 hours. In all DN transfection experi-
ments, a background vector was used as a negative con-
trol. For chemical signal blocking study, the HMEEC-1
cells were cultured for 2 days to 80% confluence. The cells
were grown overnight in basic medium without supple-
ment then pre-treated with 5 μM chemical inhibitors,
SB203580, PD98059, U0126 (Calbiochem Inc., La Jolla,
CA) or vehicle for 1 hour followed by treatment with
NTHi WCL for 4 hours.
Animal studies
10 week-old C57BL/6 male mice were used for studying
the in vivo kinetic of NTHi induced mBD-2 expression. All
aspects of animal handling were performed according to
approved HEI IACUC protocols. The mice were transtym-
panically inoculated with 10 μl of the NTHi WCL after
being anesthetized with Ketamine (5 mg/100 g). 1× PBS
solution (10 μl) was used as the negative control. At 0, 6,
9, 12 and 24 hours post-inoculation, the middle ear
mucosal RNA of three mice were harvested by irrigation of
the bulla with three, 3.5 μl volume of Trizol (Invitrogen).
The mice were sacrificed with CO2 and then decapitated.
A small incision (1 cm) was made in the retroauricular
area and the cortical bone of the bulla was exposed after
dissection. A 2 mm × 2 mm sized hole was made using aBMC Infectious Diseases 2008, 8:87 http://www.biomedcentral.com/1471-2334/8/87
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sharp scalpel followed by irrigation of the bulla with Tri-
zol. The total Trizol volume was then increased to 200 μl
and RNA was precipitated using the manufacturer's
instructions. The middle ear mucosa was inflamed in all
NTHi-treated mice, but effusion was not seen in all
groups. No sepsis or death occurred as a result of the
experimental treatment.
To compare mouse β-defensin 2 (mBD-2) expression in
TLR2 KO and wild type animals, the right ear was treated
with NTHi WCL while the left ear served as a PBS treated
control. The middle ear mucosal RNA was collected at 4
hours post-inoculation and analyzed by real-time quanti-
tative PCR.
RNA extraction and real-time quantitative RT-PCR 
analysis
RNA from cell lines or middle ear mucosa was extracted
using Trizol (Invitrogen, Carlsbad, CA) and cDNA was
synthesized using SuperScript II RNase H- reverse tran-
scriptase according to the manufacturer's protocol (Life
Technologies, Inc, Gaithersburg, MD). Applied Biosys-
tems' Assays-on-Demand primer and probe sets were then
used to perform real-time quantitative PCR on each sam-
ple. In each case, the Cyclophilin gene served as the inter-
nal standard. The assays used were as follows: 1) Defb2
(mouse  β-defensin 2), ABI assay number
Mm00657074_m1(NM_010030.1); 2) DEFB4 (human β-
defensin 2/human β-defensin 4), ABI assay number
Hs00823638_m1 (NM_004942); 3) PPID (human cyclo-
philin D), ABI assay number Hs00234593_m1
(NM_005038); 4) Ppid (mouse cyclophilin D) ABI assay
number Mm00835365_g1 (NM_026352). The relative
quantity (CT treshhold method) of β-defensin 2 mRNA
was quantitated.
Western blot analysis and kinase assays
Cells were lysed using a buffer solution containing 25 mM
TrisCl, 1 mM EDTA, 5 mM MgCl 2, 1 mM DTT, 100 mM
NaCl, 10% glycerol, 1% Triton ×-100, 1 mM PMSF, and 5
μg/ml each of leupeptin, aprotinin, and pepstatin. The
homogenate was centrifuged at 13,000 rpm for 10 min
and the supernatant collected. Protein concentration was
measured with the BCA protein assay kit (Bio-Rad, Inc.,
Richmond, CA). Cell lysates containing 50 μg of protein
were boiled for 5 min in reducing SDS-PAGE sample
buffer (0.125 Tris-HCl, pH 6.8, 4% SDS, 20% glycerol,
10% β-mercaptoethanol, and 0.2% bromophenol), and
run on SDS-PAGE. The bands were transferred to a 0.2-μm
pore nitrocellulose membrane (Whatman, Sanford, ME)
in 20% methanol, 25 mM Tris, and 192 mM glycine, pH
8.3. The membrane was blocked with 5% milk, followed
by exposure to the primary antibody (p38 α/β and phos-
pho-p38 α/β, Cell Signaling Inc., Beverly, MA). A second-
ary antibody coupled to horseradish peroxidase
(1:10,000; Amersham Biosciences) was used to bind to
the primary antibody and be detected using enhanced
chemiluminescence (NEN Life Science Products).
siRNA Transfection and ELISA
Small interfering RNA (siRNA) was used for transient gene
knock-down studies. All transient transfections were car-
ried out in triplicate using NeoFX reagent (Ambion, Aus-
tin, TX) to final concentration of 10 nM following the
manufacturer's instructions. The siRNAs used were as fol-
lows: 1) TLR2, siRNA #111285; 2) MyD88, siRNA
#11601; 3) IRAK1, siRNA #138; 4) TRAF6, siRNA
#107476; 5) MKK3, siRNA #1609; 6) MKK6, siRNA
#1321; 7) p38, siRNA #1312 and siRNA #1 for the nega-
tive control. After 20 hours, the transfected cells were
grown in fresh medium and cultured for another 48 hrs.
The efficiency of gene knock down was evaluated by either
RT-PCR or quantitative PCR. The cells were then exposed
to NTHi WCL (5 μg/ml) for either 4 hours (gene expres-
sion study) or 24 hours (measuring protein). In the latter
case, the culture supernatant was harvested and measured
by ELISA (Phoenix Pharmaceuticals, Inc., Belmont, CA).
For gene expression analysis, total RNA was isolated from
the cells and used for real-time quantitative PCR.
Statistics
All experiments were carried out in triplicate. Results are
expressed as mean ± standard deviation. The student's t-
test was used to measure significance.
Results
NTHi up-regulates β-defensin 2 expression in mucosal 
epithelial cells in vitro and in vivo
In vitro
To find out whether NTHi can increase expression of
HBD-2 mRNA in vitro, we first treated human middle ear
epithelial cells (HMEEC-1) with various NTHi prepara-
tions – live NTHi, WCL, pellet, and lipooligosaccharide
(LOS). The greatest induction of HBD-2 expression was
observed with the NTHi WCL preparation, which suggests
that the ligand(s) may be a soluble protein. Even though
the other preparations also induced HBD-2, the levels
were negligible compared to that of WCL (Fig 1A). Similar
experiments using WCL preparations from different
strains of NTHi showed no significant differences between
the various NTHi strains in inducing HBD-2 expression
(Fig 1B). Fig 2A shows the kinetics of HBD-2 expression
upon exposure to 5 μg/ml of NTHi WCL. As is evident
from the figure, the expression peaked at 4 hours post-
treatment then gradually waned out. The induction of
HBD-2 by NTHi was also observed in A549 cells (a human
lung carcinoma cell line), with near-maximal levels of
expression occurring at 8 hours post-treatment (Fig 2B).BMC Infectious Diseases 2008, 8:87 http://www.biomedcentral.com/1471-2334/8/87
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In vivo
Mice middle ear epithelium inoculated with 10 μl of
NTHi WCL showed very similar kinetics to the in vitro cell
line data above (Fig 2C).
The TLR2-depedent MyD88-IRAK-TRAF6 signaling 
cascade is involved in NTHi-induced up-regulation of β-
defensin 2 mRNA
Antibody blocking and knock-out animal experiment
Having demonstrated that NTHi can up-regulate β-
defensin 2 mRNA in HMEEC-1, we next sought to identify
Induction of β-defensin 2 (HBD-2) in human middle ear epithelial cells (HMEEC-1) using various NTHi preparations or NTHi  variants Figure 1
Induction of β-defensin 2 (HBD-2) in human middle ear epithelial cells (HMEEC-1) using various NTHi prepa-
rations or NTHi variants. With the exception of lipoolygosaccharide (LOS), all other NTHi preparations were derived 
from the same colony of NTHi strain 12. The LOS was purified from NTHi 12 and used at a concentration of 500 ng/ml. Live 
NTHi12 was treated using an multiplicity of infection (MOI) of 100 and NTHi WCL (whole cell lysate) and P (Pellet) were used 
at a concentration of 5 μg/ml. (A), The WCL treatment induced substantially higher expression of HBD-2 than other prepara-
tions. (B), Different strains of NTHi WCL were prepared and treated at the same concentration (5 μg/ml). The induction of 
HBD-2 mRNA was not significantly different between the tested strains. Values are given as mean ± standard deviation. N = 3. 
*: p < 0.05.
0
2
4
6
8
10
12
14
16
18
Control
NTHi 12 
NTHi 2019
NTHi 9274
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
H
B
D
-
2
 
m
R
N
A
 
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
B
0
5
10
15
20
25
30
35
Control LOS Live WCL P
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
H
B
D
-
2
 
m
R
N
A
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
*
A
0
2
4
6
8
10
12
14
16
18
Control
NTHi 12 
NTHi 2019
NTHi 9274
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
H
B
D
-
2
 
m
R
N
A
 
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
B
0
2
4
6
8
10
12
14
16
18
Control
NTHi 12 
NTHi 2019
NTHi 9274
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
H
B
D
-
2
 
m
R
N
A
 
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
B
0
5
10
15
20
25
30
35
Control LOS Live WCL P
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
H
B
D
-
2
 
m
R
N
A
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
*
A
0
5
10
15
20
25
30
35
Control LOS Live WCL P
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
H
B
D
-
2
 
m
R
N
A
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
*
A
NTHi whole cell lysate (WCL) up-regulates β-defensin 2 (HBD-2) gene expression in immortalized human mucosal epithelial  cells (HMEEC-1) Figure 2
NTHi whole cell lysate (WCL) up-regulates β-defensin 2 (HBD-2) gene expression in immortalized human 
mucosal epithelial cells (HMEEC-1). NTHi treatment of HMEEC-1 (A) and A549 epithelial cells (B) increased the mRNA 
levels of β-defensin 2. The x-axis shows the time during which the cells were exposed to NTHi WCL (5 μg/ml). The y-axis rep-
resents the signal derived from quantitative PCR on total RNA extracted from the cells. (C), NTHi also up-regulates mouse β-
defensin 2 (mBD-2) mRNA expression in the mouse middle ear, in vivo. NTHi WCL (10 μl) was transtympanically inoculated 
into the middle ears of anesthetized C57BL/6J mice. Animals were sacrificed at the indicated time points and total RNA 
extracted from the middle ear mucosa (n = 3). Values are given as mean ± standard deviation.
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the cell surface receptor that is responsible for recognizing
NTHi ligand(s) and initiating the appropriate signaling
cascade. Pre-incubation of HMEEC-1 with a TLR2 specific
blocking antibody dramatically reduced the expression of
HBD-2 in HMEEC-1 cell culture in response to NTHi WCL
treatment (Fig 3A), indicating that TLR2 plays a major role
in this pathway. The importance of TLR2 in NTHi WCL-
induced β-defensin 2 production was also tested in gene
knock out animals. The induction rate of mBD-2 expres-
sion in TLR2 KO mice middle ear epithelial cells in
response to NTHi WCL was substantially lower than that
of wild type mice (Fig 3B). This in vivo experiment con-
firmed the critical role of TLR2 in NTHi induced cell sign-
aling that resulted in the production of the highly potent
antimicrobial innate immune molecule – β-defensin 2 –
by the middle ear epithelial cells.
siRNA
We also used TLR2 knock-down experiments to assess the
involvement of TLR2 in the pathway using small interfer-
ing RNA (siRNA) specific for TLR2. As shown in Fig 4A,
HBD-2 induction by NTHi was inhibited in the presence
of TLR2-specific siRNAs. Furthermore, similar siRNA
experiments also revealed the involvements of inter-
leukin-1 receptor-associated kinase 1 (IRAK1) and tumor
necrosis factor receptor-associated factor 6 (TRAF6) (Fig
4A) as well as MKK3/6 and p38 MAPK (Fig 4B) in NTHi
induced  β-defensin expression. The efficiency of gene
knock down was confirmed by either RT-PCR (Fig 4C) or
quantitative PCR (Fig 4D). The Q-PCR results showed 60–
70% reduction of target gene expression in TLR2, IRAK1,
MKK6 and p38 siRNA treated HMEEC-1 compared with
those of negative control siRNA treated cells (Fig 4D). In
the presence of 5 μg/ml of NTHi WCL for 24 hours, β-
defensin 2 production was also inhibited when cells were
transfected with TLR2, IRAK1, MKK3 and MKK6 siRNAs,
indicating the direct involvement of these proteins in
mediating the NTHi-induced HBD-2 expression (Fig 4E).
Dominant negative (DN) plasmids
To validate the involvement of MyD88, IRAK1, and
TRAF6 in the pathway, we over-expressed dominant-neg-
ative mutant (DN) plasmids of each gene associated with
the pathway. TLR2 DN, but not TLR4 DN, resulted in inhi-
bition of HBD-2 expression, confirming that TLR2 is the
main receptor that mediates NTHi signaling through
induction of β-defensin 2 (Fig 5A). The adaptor molecule
MyD88 has previously been shown [13,35] to be the first
molecule in the signaling cascade, immediately down-
stream of TLR2. Cells treated with MyD88DN show a sub-
stantial reduction in HBD-2 expression (Fig 5A),
validating the involvement of this molecule in the path-
The TLR2 blocking antibody inhibition of NTHi induced HBD-2 mRNA expression in HMEEC-1 cells and in TLR2 knock out  mice Figure 3
The TLR2 blocking antibody inhibition of NTHi induced HBD-2 mRNA expression in HMEEC-1 cells and in 
TLR2 knock out mice. (A) Pretreatment of HMEEC-1 with human TLR2 blocking antibody for 30 minutes (10 μg/ml, clone 
TL2.1, eBioscience) reduced the HBD-2 mRNA expression dramatically in response to NTHi lysate stimulation (5 μg/ml). In 
contrast, human TLR4 blocking antibody did not show any significant effect suggesting that TLR2 is one of the major signaling 
receptors for inducing human β-defensin 2 expression in response to NTHi stimulation in HMEEC-1. The control group was 
treated with an isogenic antibody. (B) NTHi WCL-induced expression of murine β-defensin 2 mRNA (mBD-2) in wild type 
(C57 BL/6) and TLR2-/- mice was compared. Mice were injected with 10 μl of NTHi WCL transtympanically in the left ear. The 
right ear served as a PBS injected control. Four hours post-injection, the total RNA was harvested and Defb2 expression meas-
ured by quantitative PCR (n = 3). Values are given as mean ± standard deviation. N = 3. *: p < 0.05.
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way. The reduction of HBD-2 expression in IRAK1 and
TRAF6 dominant-negative mutants over-expressed cells
confirmed the involvement of these genes in the NTHi
induced up-regulation of HBD-2 (Fig 5B).
The p38 MAP Kinase pathway is involved in the up-
regulation of β-defensin 2 by NTHi
As shown in Fig 5C, treatment of HMEEC-1 with NTHi
WCL (5 μg/ml) results in the rapid phosphorylation of
p38 MAPK protein. The phosphorylation peaked at 45
minutes post-treatment and rapidly disappeared 60 min-
NTHi-induced HBD-2 expression in HMEEC-1 utilizes the TLR2-dependent IRAK-TRAF6-p38MAPK signaling cascade Figure 4
NTHi-induced HBD-2 expression in HMEEC-1 utilizes the TLR2-dependent IRAK-TRAF6-p38MAPK signaling 
cascade. (A and B) Cells treated with siRNA specific for TLR2, interleukin receptor associated kinase 1 (IRAK1), tumor 
necrosis factor receptor associated factor 6 (TRAF6), MAP kinase kinase 3 (MKK3), MKK6 and p38 showed significantly lower 
HBD-2 expression compared to a negative control. (C) The targeted gene knock down using siRNA was confirmed either by 
RT-PCR or(D) quantitative PCR. (E) Reduced HBD-2 peptide production in the HMEEC-1 cells treated with target specific 
siRNA, after treatment with NTHi lysate. The siRNA knock down cells were treated with NTHi lysate for 24 hours. The cul-
ture supernatant was collected and HBD-2 protein levels were measured by ELISA. The HBD-2 secretion from cells with tar-
get gene knock down was substantially lower than in negative siRNA treated controls. In experiments A, B, D and E, values are 
given as mean ± standard deviation. N = 3. *: p < 0.05.
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utes after treatment. Exposure to SB203580, a specific
inhibitor of p38 α and β, exhibited an inhibition in β-
defensin 2 expression, while treatment with PD98059 and
U0126, both inhibitors of MEK, did not show any signifi-
cant effects (Fig 5D).
Discussion
Antimicrobial innate immune molecules produced by the
epithelial cells provide the host with a constitutive or
immediately inducible defense mechanism against invad-
ing pathogens. Under normal conditions, the middle ear
of humans and laboratory animals remains sterile,
although OM pathogens, which are part of the normal
nasopharyngeal flora can reach the middle ear via the Eus-
tachian tube causing infection [45]. Furthermore, non-
inflamed tubal and middle ear mucosa have been shown
to contain relatively few immunocytes [46,47]. All of
these findings suggest that the components of the innate
(A) TLR2 and MyD88 dominant-negative (DN) mutants, but not TLR4 DN mutant, inhibit NTHi-induced up-regulation of  HBD-2 expression Figure 5
(A) TLR2 and MyD88 dominant-negative (DN) mutants, but not TLR4 DN mutant, inhibit NTHi-induced up-
regulation of HBD-2 expression. (B) The MyD88 downstream signaling proteins, IRAK1 and TRAF6 are also involved in 
this up-regulation. (C) The kinetics of P38 phosphorylation: phosphorylation of p38 MAPK started at 15 minutes post-treat-
ment, peaked at 45 minutes post-treatment and then disappeared after 60 minutes. (D) Inhibition of p38 MAPK by SB203580, 
a specific inhibitor of p38, abolishes HBD-2 up-regulation by NTHi. Cells were pretreated with 5 μM of SB203580, PD98059, 
and U0126 for 1 hour and then treated with NTHi WCL (5 μg/ml) for 4 hours. Only SB203580 exhibited inhibitory activity 
towards NTHi WCL-specific HBD-2 expression. The ERK inhibitors, PD98059 and U0126 showed little or no effect. In exper-
iments A, B and D, values are given as mean ± standard deviation. N = 3. *: p < 0.05.
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immune system may be important in the defense of the
tubotympanum (middle ear and Eustachian tube). Fur-
thermore, due to the premature and under-developed
adaptive immune system in infants and young children,
the role of AIIMs in protecting against OM pathogens
becomes of paramount importance. Park and Lim [10]
showed that the lysozyme positive cells in the epithelium
and glandular structures of the Eustachian tube of adult
and early post-natal animals were similar. Our previous
studies also showed synergistic antimicrobial activities of
AIIMs against OM pathogens [8,14]. These results lend
strong support to the hypothesis that AIIMs protect the
tubotypmpanum during the neonatal and early postnatal
periods when the adaptive immunity is not yet fully devel-
oped.
Among the AIIMs, β-defensin 2 plays a pivotal role against
major OM pathogens and previous studies have shown
that this molecule is inducible by a variety of agents,
including cytokines, NTHi and its components/molecules
[8,14,23,27,30]. Furthermore, we have previously shown
that this molecule is expressed at high levels in the middle
ear mucosa of patients with OM, but it is undetectable in
the normal middle ear mucosa [27].
Some LOS mutants of NTHi exhibit reduced virulence and
require higher doses in order to induce OM [48]. Muta-
tions in certain bacterial membrane components alter the
susceptibility of the mutants towards AIIMs [49,50]. How-
ever, these mutations did not significantly affect the
inducibility of HBD-2 expression. To date, the exact
nature and identity of the β-defensin 2 inducing mole-
cule(s) remains elusive, but what is known is that it is
maximally active and is present in the soluble WCL por-
tion (Fig 1A and 1B) [51]. Currently several NTHi macro-
molecules have been identified as vaccine candidates,
which include adhesins, high molecular weight adhesins,
pilus proteins, outer membrane proteins and LOS [52-
55]. Identification of induction of the responsible ligand
for beta-defensin 2 requires more research.
Treatment with NTHi WCL causes a substantial increase in
HBD-2 mRNA expression in both HMEEC-1 and A549
cells. However, the kinetics of HBD-2 expression is a little
different between the two cell lines (Fig 2A and 2B), which
may be the result of the fact that different cells respond
differently even to the same bacterial components [20]. In
vivo induction of mouse β defensin-2 with NTHi WCL
treated mice middle ear epithelia exhibits a similar trend
to that of HMEEC-1; the mRNA level peaked at 6 hour
post-inoculation and dropped back down to basal levels
by 12 hours (Fig 2C). This rapid increase in mouse β
defensin-2 levels may indicate that the middle ear epithe-
lial cells, but not inflammatory cells, were the sole source
of the mouse β defensin-2 mRNA – β defensins are mainly
produced by epithelial cells since monocytes would not
have yet begun infiltrating the middle ear cavity during
this period [56].
The Toll-like receptors (TLRs) have been shown to be crit-
ical for the recognition of bacteria and recent studies have
demonstrated that TLR2 and TLR4 are involved in NTHi
signaling [3,57]. To test the involvement of either TLR2 or
TLR4 in mediating NTHi WCL induced HBD-2 up-regula-
tion, we used blocking antibodies, siRNA, and dominant
negative mutants of TLR2 and TLR4 to inhibit the recep-
tors' activities (Figs 3 – 5). All three methods revealed
TLR2 as being the primary receptor for the recognition of
NTHi WCL component.
Based on these results, we investigated the role and iden-
tity of other possible players downstream of the TLR2
pathway that may be involved in HBD-2 up-regulation by
the NTHi WCL such as MyD88, which was previously
shown to be the first molecule in the signaling cascade
immediately downstream of the TLR2 [13] and its associ-
ated proteins, interleukin-1 receptor-associated kinase 1
(IRAK1) [13,19] and tumor necrosis factor receptor-asso-
ciated factor 6 (TRAF6). MyD88 is recruited via its TIR
death domain and promotes association and phosphor-
ylation of the IRAK1. The phosphorylation of IRAK1
results in its dissociation from the complex and its inter-
action with TRAF6. This interaction results in the activa-
tion of downstream signaling in the majority of the
epithelial cells studied [13,19]. Our results using siRNA
(Fig 4A, 4B &4E) and DN plasmids (Fig 5A &5B) indicate
that MyD88, IRAK1 & TRAF6 are directly involved in reg-
ulating HBD-2 expression in the presence of NTHi WCL.
Activation of the TLR2-MyD88-IRAK1-TRAF6 can lead to
the activation of many downstream signaling pathways,
including members of the mitogen-activated protein
kinase (MAPK) family [19,35]. Previous studies have sug-
gested that the p38 MAPK pathway is involved in HBD-2
induction in other cell systems [20,58,59]. We therefore
sought to determine if p38 MAPK can act as a major sign-
aling mediator for NTHi induced β-defensin 2 expression.
Indeed, our results support data from previous work since
such up-regulation was greatly inhibited by SB203580, a
specific inhibitor of p38 MAPK but not by ERK inhibitors
such as PD98059 and U0126. Also we used siRNA gene
knock down to confirm the involvement of p38 MAPK
and its associated upstream activators – MKK3 and MKK6.
The results (Fig 4B &4E) support our hypothesis that
NTHi WCL-specific HBD-2 up-regulation in HMEEC-1
takes place through the p38 MAPK cascade. The kinetics of
this signaling was very rapid; phosphorylation of p38
MAPK started 15 minutes after stimulation and peaked at
45 minutes (Fig 5C). Near complete dephosphorylation
was achieved by 60 minutes post-stimulation. Secretion ofBMC Infectious Diseases 2008, 8:87 http://www.biomedcentral.com/1471-2334/8/87
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the β-defensin 2 was also reduced in cells treated with siR-
NAs targeted for down-regulating TLR2, IRAK1, TRAF6,
and MKK(3/6) signaling molecules compared to a nega-
tive control. The importance of the role of TLR2 in NTHi
WCL induced β-defensin 2 expression was also confirmed
in vivo. The induction of mouse β-defensin 2 (mBD-2)
mRNA by NTHi WCL in TLR2 KO mice middle ear was
much lower than that of an age matched wild type con-
trol.
Beta-defensin exhibits not only innate immune activity
such as direct killing of invading bacteria but also has
been known to mediate adaptive immunity [60]. The
secreted β-defensin functions as an chemoattractant for
CCR6 positive immature dendritic and memory T cells,
facilitating the transition from innate immunity to adap-
tive immunity by producing inflammatory cytokines and
chemokines such as IL-1 [19,60-62]. Our previous studies
showed that IL-1α is a potent inducer of β-defensin 2 and
acts synergistically with NTHi WCL to up-regulate β-
defensin 2 expression [27,30]. These experiments showed
that IL-1α-induced β-defensin 2 expression was mediated
through the Src-dependent Raf-MEK1/2-ERK MAPK path-
way and uses the same TIR domain of TLR2 that recog-
nizes the unknown NTHi WCL component [27,34]. The
synergism between IL-1α and NTHi may be explained as
follows: NTHi WCL stimulates HMEEC-1 through MyD88
dependent TLR2 signaling pathway inducing an early
phase response with subsequent β-defensin 2 and proin-
flammatory cytokine (such as IL-1α) production [13,34].
The secreted IL-1α may further stimulate the cells through
MyD88 independent IL-1R pathway that initiates a late
phase response [13,34]. Therefore, even though active
NTHi component/ligand and IL-1α utilize the same TIR
domain and are working through the p38 and ERK MAPK
signaling pathways respectively, they can act synergisti-
cally to amplify β-defensin 2 expression [13,34,63].
Recently a new group of receptors, Nacht-LRR, NOD-like
Receptor, or CATERPILLAR (NLR), has been reported that
resemble and function as intracellular receptors for bacte-
rial recognition [19,64,65]. These receptors not only rec-
ognize invasive microbes and appropriate bacterial
components/ligands, but also play pivotal roles in trigger-
ing inflammatory response by converting the inactive
forms of pro-cytokines to active mature cytokines [66,67].
Based on these facts, we speculate that these intracellular
receptors may contribute to increasing the NTHi induced
β-defensin 2 expression in HMEEC-1. Although NTHi is
considered as a mucosal surface pathogen, there have
been reports that NTHi can be internalized in the mucosal
epithelium [68,69]. While the significance of this bacterial
internalization in the pathogenesis of otitis media is not
yet known, it is possible that such internalized bacterial
components can also induce β-defensin up-regulation.
Studies are currently underway in our laboratory to test
this possibility.
Conclusion
In conclusion, we have observed that NTHi WCL signals
through a TLR2 dependent TIR domain similar to IL-1α.
However, this is where the similarities end: Both NTHi
WCL and IL-1α signal through entirely different sets of
downstream players, possibly leading to a synergistic
induction of HBD-2 in infection.
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